Inhibikase Therapeutics (IKT) Misses Q1 EPS by 10c

Inhibikase Therapeutics (NASDAQ: IKT) reported Q1 EPS of ($0.10).

For earnings history and earnings-related data on Inhibikase Therapeutics (IKT) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance
• Boeing wins $13.4 billion contract modification from US military